Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens

Top Cited Papers
Open Access
Publisher Website
Google Scholar
Abstract
No mucosal adjuvant formulation is approved for clinical use, even though boosting immunity at sites of pathogen entry should increase the efficacy of nonreplicating vaccines. Wegmann et al. report that polyethyleneimine (PEI) acts as a potent mucosal adjuvant for protein antigens from influenza and herpes simplex virus, protecting mice against otherwise lethal infections. Protection against mucosally transmitted infections probably requires immunity at the site of pathogen entry1, yet there are no mucosal adjuvant formulations licensed for human use. Polyethyleneimine (PEI) represents a family of organic polycations used as nucleic acid transfection reagents in vitro and DNA vaccine delivery vehicles in vivo2,3. Here we show that diverse PEI forms have potent mucosal adjuvant activity for viral subunit glycoprotein antigens. A single intranasal administration of influenza hemagglutinin or herpes simplex virus type-2 (HSV-2) glycoprotein D with PEI elicited robust antibody-mediated protection from an otherwise lethal infection, and was superior to existing experimental mucosal adjuvants. PEI formed nanoscale complexes with antigen, which were taken up by antigen-presenting cells in vitro and in vivo, promoted dendritic cell trafficking to draining lymph nodes and induced non-proinflammatory cytokine responses. PEI adjuvanticity required release of host double-stranded DNA that triggered Irf3-dependent signaling. PEI therefore merits further investigation as a mucosal adjuvant for human use.